Functional consequences of mutations in the myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy.

The primary cause of familial hypertrophic cardiomyopathy (FHC) has been attributed to mutations in the genes that encode the contractile proteins of the muscle cell. A majority of these mutations have been found in myosin, the principal component of the thick filament. Most in vitro studies have concluded that FHC mutations cause a loss of function in the biochemical and mechanical properties of myosin. Hypertrophy would then follow as a compensatory mechanism to raise the work and power output of the failing heart. Several recent studies, however, have thrown this mechanism into doubt by providing evidence that FHC mutations in the myosin heavy chain (MHC) can enhance the functional properties of myosin. This review discusses the problems encountered in reaching a definitive answer on the effect of MHC mutations.

[1]  Frederick J. Schoen,et al.  A Mouse Model of Familial Hypertrophic Cardiomyopathy , 1996, Science.

[2]  Matthew J. Tyska,et al.  R403Q and L908V mutant β-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level , 2004, Journal of Muscle Research & Cell Motility.

[3]  Dm Warshaw,et al.  THE IN VITRO MOTILITY ASSAY : A WINDOW INTO THE MYOSIN MOLECULAR MOTOR , 1996 .

[4]  B. Hainque,et al.  Familial hypertrophic cardiomyopathy: from mutations to functional defects. , 1998, Circulation research.

[5]  W. Zhu,et al.  Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy. , 1993, The Journal of clinical investigation.

[6]  Roberto Dominguez,et al.  Crystal Structure of a Vertebrate Smooth Muscle Myosin Motor Domain and Its Complex with the Essential Light Chain Visualization of the Pre–Power Stroke State , 1998, Cell.

[7]  H M Holden,et al.  X-ray structures of the myosin motor domain of Dictyostelium discoideum complexed with MgADP.BeFx and MgADP.AlF4-. , 1995, Biochemistry.

[8]  D A Winkelmann,et al.  Three-dimensional structure of myosin subfragment-1: a molecular motor. , 1993, Science.

[9]  R. Roberts,et al.  Accumulation and assembly of myosin in hypertrophic cardiomyopathy with the 403 Arg to Gln beta-myosin heavy chain mutation. , 1992, Circulation research.

[10]  M. Bárány,et al.  ATPase Activity of Myosin Correlated with Speed of Muscle Shortening , 1967, The Journal of general physiology.

[11]  L. Leinwand,et al.  Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. , 1994, The Journal of biological chemistry.

[12]  L. Leinwand,et al.  Contractile protein mutations and heart disease. , 1996, Current opinion in cell biology.

[13]  J. Sellers,et al.  The in vitro motility activity of β-cardiac myosin depends on the nature of the β-myosin heavy chain gene mutation in hypertrophic cardiomyopathy , 1997, Journal of Muscle Research & Cell Motility.

[14]  R A Milligan,et al.  Structure of the actin-myosin complex and its implications for muscle contraction. , 1993, Science.

[15]  H. Sugi,et al.  Characterization of mutant myosins of Dictyostelium discoideum equivalent to human familial hypertrophic cardiomyopathy mutants. Molecular force level of mutant myosins may have a prognostic implication. , 1997, The Journal of clinical investigation.

[16]  T. Hewett,et al.  Expression of the beta (slow)-isoform of MHC in the adult mouse heart causes dominant-negative functional effects. , 2000, American journal of physiology. Heart and circulatory physiology.

[17]  K. Trybus,et al.  Smooth muscle myosin cross-bridge interactions modulate actin filament sliding velocity in vitro , 1990, The Journal of cell biology.

[18]  H E Huxley,et al.  The Mechanism of Muscular Contraction , 1965, Scientific American.

[19]  L. Kunkel,et al.  Dystrophin abnormalities in Duchenne/Becker muscular dystrophy , 1989, Neuron.

[20]  L. Fananapazir,et al.  Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. , 2000, Journal of molecular and cellular cardiology.

[21]  A J Marian,et al.  A transgenic rabbit model for human hypertrophic cardiomyopathy. , 1999, The Journal of clinical investigation.

[22]  N. Alpert,et al.  Cardiac V1 and V3 myosins differ in their hydrolytic and mechanical activities in vitro. , 1995, Circulation research.

[23]  L. Leinwand,et al.  Full-length rat alpha and beta cardiac myosin heavy chain sequences. Comparisons suggest a molecular basis for functional differences. , 1989, Journal of molecular biology.

[24]  J. Seidman,et al.  Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. , 2000, Circulation research.

[25]  R. Cooke,et al.  The mechanism of muscle contraction. , 1986, CRC critical reviews in biochemistry.

[26]  M. Ikebe,et al.  Functional analysis of the mutations in the human cardiac beta-myosin that are responsible for familial hypertrophic cardiomyopathy. Implication for the clinical outcome. , 1996, The Journal of clinical investigation.

[27]  L. Leinwand,et al.  Functional analysis of myosin mutations that cause familial hypertrophic cardiomyopathy. , 1998, Biophysical journal.

[28]  M. Tyska,et al.  Functional consequences of mutations in the smooth muscle myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy. , 2000, The Journal of biological chemistry.

[29]  J. Seidman,et al.  A molecular basis for familial hypertrophic cardiomyopathy: A β cardiac myosin heavy chain gene missense mutation , 1990, Cell.

[30]  Niels Volkmann,et al.  Evidence for cleft closure in actomyosin upon ADP release , 2000, Nature Structural Biology.

[31]  D. Mann,et al.  Expression of a Mutation Causing Hypertrophic Cardiomyopathy Disrupts Sarcomere Assembly in Adult Feline Cardiac Myocytes , 1995 .

[32]  I. Rayment,et al.  Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  K C Holmes,et al.  Structural mechanism of muscle contraction. , 1999, Annual review of biochemistry.

[34]  H. Bunn Pathogenesis and treatment of sickle cell disease. , 1997, The New England journal of medicine.